Oriane Cédile

Dr. Oriane Cédile

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2014 in Journal of Autoimmunity
Verified
Journal Article
Closed access
OCOriane Cédile
Oriane Cédile
MLM. Løbner
M. Løbner
HTH. Toft-Hansen
H. Toft-Hansen
IFI. Frank
I. Frank
AWAgnieszka Wlodarczyk
Agnieszka Wlodarczyk
Trevor OwensTrevor Owens
Trevor Owens

1 June 2021 in Experimental Hematology
Verified
Journal Article
Open access
MHMarcus Høy Hansen
Marcus Høy Hansen
OCOriane Cédile
Oriane Cédile
TLThomas S. Larsen
Thomas S. Larsen
NANiels Abildgaard
Niels Abildgaard
CNCharlotte G. Nyvold
Charlotte G. Nyvold
Malignant lymphoproliferative disorders collectively constitute a large fraction of the hematological cancers, ranging from indolent to highly aggressive neoplasms. Being a diagnostically important hallmark, clonal gene rearrangements of the immunoglobulins enable the detection of residual disease in the clinical course of the patients down to a minute fraction of malignant cells. The introduction of next-generation sequencing has provided unprecedented assay specificity, with a sensitivity matching that of PCR-based measurable residual disease (MRD) detection down to the 10-6 level. While reaching 10-6-10-7 is theoretically feasible, employing a sufficient amount of DNA and sequencing coverage is put in the perspective of the practical challenges when relying on clinical samples in contrast to controlled serial dilutions. As we discuss, the randomness of subsampling must be taken into account to accommodate the sensitivity threshold - both in terms of the required number of cells and sequencing coverage. As a substantial part of the reviewed studies do not state the depth of coverage or even amount of DNA in some cases, we call for increased transparency in order to enable critical assessment of the MRD assays for clinical implementation and feasibility.

1 December 2017 in Immunology Letters
Verified
Journal Article
Open access
OCOriane Cédile
Oriane Cédile
LJLine Østerby Jørgensen
Line Østerby Jørgensen
IFIda Frank
Ida Frank
AWAgnieszka Wlodarczyk
Agnieszka Wlodarczyk
Trevor OwensTrevor Owens
Trevor Owens
Thymic dendritic cells (DC) play a role in central tolerance. Three thymic DC subtypes have been described: plasmacytoid DC (pDC) and two conventional DC (cDC), CD8α+ Sirpα- DC and Sirpα+ CD8α- cDC. Both pDC and Sirpα+ cDC can take up antigen in periphery and migrate into the thymus in response to chemokine signaling via CCR9 and CCR2 respectively. CCL2 is a major ligand for CCR2 and we previously showed that it was constitutively expressed in thymus, and that mice overexpressing CCL2 in thymus had reduced numbers of autoreactive T cells but elevated numbers of pDC. We have here investigated the role of CCL2-CCR2 axis in thymic pDC migration. We found that pDC expressed CCR2 at a high level and that their frequency was decreased in thymus, spleen and inguinal lymph nodes in mice lacking CCR2, but not in mice lacking CCL2. pDC migration towards the cortex or medulla within the thymus was not affected by CCL2 or CCR2 deficiency. Although some thymic progenitors expressed CCR2, this did not include those that give rise to pDC. Based on these results, we propose that CCR2 is involved in pDC homeostasis but its ligand CCL2 does not play a major role.

1 April 2020 in Experimental Hematology
Verified
Journal Article
Closed access
MHMarcus Høy Hansen
Marcus Høy Hansen
OCOriane Cédile
Oriane Cédile
MBMia Koldby Blum
Mia Koldby Blum
SHSimone Valentin Hansen
Simone Valentin Hansen
LELene Hyldahl Ebbesen
Lene Hyldahl Ebbesen
CNCharlotte Guldborg Nyvold
Charlotte Guldborg Nyvold

7 September 2023 in The Journal of Molecular Diagnostics
Verified
Journal Article
Open access
MHMarcus Høy Hansen
Marcus Høy Hansen
OCOriane Cédile
Oriane Cédile
MKMarie L.G. Kjeldsen
Marie L.G. Kjeldsen
MTMads Thomassen
Mads Thomassen
BPBirgitte Preiss
Birgitte Preiss
CNCharlotte G. Nyvold
Charlotte G. Nyvold
The current advances and success of next-generation sequencing hold the potential for the transition of cancer cytogenetics toward comprehensive cytogenomics. However, the conventional use of short reads impedes the resolution of chromosomal aberrations with current next-generation sequencing modalities. Thus, this study evaluated the detection and reproducibility of extensive copy number alterations and chromosomal translocations using long-read Oxford Nanopore Technologies whole-genome sequencing compared with short-read Illumina sequencing. On the basis of the mantle cell lymphoma cell line Granta-519, almost 99% copy number reproducibility at the 100-kilobase resolution between replicates was demonstrated, with 98% concordance to Illumina. Collectively, the performance of copy number calling from 1.5 million to 7.5 million long reads was comparable to 1 billion Illumina-based reads (50× coverage). Expectedly, the long-read resolution of canonical translocation t(11; 14) (q13; q32) was superior, with a sequence similarity of 89% to the already published CCND1/IGH junction (9× coverage), spanning up to 69 kilobases. The cytogenetic profile of Granta-519 was in general agreement with the literature and karyotype, although several differences remained unresolved. In conclusion, contemporary long-read sequencing is primed for future cytogenomics or sequencing-guided cytogenetics. The combined strength of long- and short-read sequencing is apparent, where the high-precision junctional mapping complements and splits paired-end reads. The potential is emphasized by the flexible single-sample genomic data acquisition of Oxford Nanopore Technologies with the high resolution of allelic imbalances using Illumina short-read sequencing.

16 October 2025 in Blood Advances
Verified
Journal Article
Open access
GVGayaththri Vimalathas
Gayaththri Vimalathas
MHMarcus Høy Hansen
Marcus Høy Hansen
OCOriane Cédile
Oriane Cédile
MTmads Thomassen
mads Thomassen
MMMichael Boe Møller
Michael Boe Møller
TLThomas Stauffer Larsen
Thomas Stauffer Larsen
Positron emission tomography–computed tomography (PET-CT) is recommended for response evaluation in aggressive large B-cell lymphoma (LBCL) but cannot detect minimal residual disease (MRD). Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for real-time disease monitoring. This study evaluated longitudinal ctDNA monitoring as an MRD marker in LBCL. In this prospective, single-center study, 14 newly diagnosed patients with LBCL receiving first-line immunochemotherapy underwent frequent longitudinal blood sampling. A 53-gene targeted sequencing panel quantified ctDNA and evaluated its kinetics, correlating it with clinical parameters and PET-CT, including total metabolic tumor volume (TMTV) calculated using artificial intelligence–based analysis via RECOMIA. Baseline ctDNA was detected in 11 of 14 patients (79%) with a median variant allele frequency of 6.88% (interquartile range, 1.19%-10.20%). ctDNA levels correlated significantly with TMTV (ρ = 0.90; P < .0001) and lactate dehydrogenase. ctDNA kinetics, including after 1 treatment cycle, mirrored PET-CT metabolic changes and identified relapsing or refractory patients. This study demonstrates ctDNA-based MRD monitoring in LBCL using a fixed targeted assay with an analytical sensitivity of at least 10−3. The kinetics of ctDNA reflects the clinical course and PET-CT findings, underscoring its complementary potential to PET-CT.